CME Group (NASDAQ:CME) PT Raised to $250.00

CME Group (NASDAQ:CME) had its target price lifted by stock analysts at Citigroup from $240.00 to $250.00 in a report issued on Thursday, Benzinga reports. The brokerage currently has a “buy” rating on the financial services provider’s stock. Citigroup’s price target suggests a potential upside of 11.29% from the company’s previous close.

Other equities analysts have also recently issued reports about the stock. Piper Sandler reissued an “overweight” rating and set a $225.00 price target on shares of CME Group in a research report on Tuesday, August 20th. The Goldman Sachs Group boosted their price target on shares of CME Group from $195.00 to $198.00 and gave the stock a “sell” rating in a research report on Thursday. Barclays boosted their price objective on shares of CME Group from $208.00 to $209.00 and gave the stock an “equal weight” rating in a research note on Thursday, July 25th. TD Cowen initiated coverage on shares of CME Group in a research note on Thursday, September 26th. They set a “hold” rating and a $221.00 price objective on the stock. Finally, Deutsche Bank Aktiengesellschaft upped their price target on shares of CME Group from $193.00 to $200.00 and gave the company a “hold” rating in a research note on Thursday, August 15th. Four research analysts have rated the stock with a sell rating, seven have given a hold rating and three have assigned a buy rating to the company. According to MarketBeat.com, the company has a consensus rating of “Hold” and an average target price of $213.77.

CME Group Price Performance

Shares of CME Group stock traded up $1.06 during midday trading on Thursday, reaching $224.63. The company had a trading volume of 1,014,829 shares, compared to its average volume of 1,957,318. The stock has a fifty day simple moving average of $211.20 and a 200 day simple moving average of $207.59. The company has a current ratio of 1.02, a quick ratio of 1.02 and a debt-to-equity ratio of 0.10. CME Group has a 1-year low of $190.70 and a 1-year high of $226.78. The company has a market capitalization of $80.88 billion, a price-to-earnings ratio of 25.56, a price-to-earnings-growth ratio of 8.74 and a beta of 0.55.

CME Group (NASDAQ:CME) last released its earnings results on Wednesday, July 24th. The financial services provider reported $2.56 EPS for the quarter, topping analysts’ consensus estimates of $2.53 by $0.03. The firm had revenue of $1.53 billion during the quarter, compared to analyst estimates of $1.53 billion. CME Group had a net margin of 56.98% and a return on equity of 12.82%. The business’s quarterly revenue was up 12.7% compared to the same quarter last year. During the same quarter in the previous year, the business earned $2.30 EPS. As a group, equities research analysts forecast that CME Group will post 9.94 earnings per share for the current year.

Insider Transactions at CME Group

In related news, Director Bryan T. Durkin sold 7,593 shares of the stock in a transaction that occurred on Friday, August 30th. The shares were sold at an average price of $214.59, for a total value of $1,629,381.87. Following the completion of the transaction, the director now owns 55,607 shares of the company’s stock, valued at approximately $11,932,706.13. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website. In other news, Director Bryan T. Durkin sold 7,593 shares of CME Group stock in a transaction on Friday, August 30th. The shares were sold at an average price of $214.59, for a total transaction of $1,629,381.87. Following the transaction, the director now owns 55,607 shares in the company, valued at $11,932,706.13. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, CFO Lynne Fitzpatrick sold 754 shares of CME Group stock in a transaction on Sunday, September 15th. The stock was sold at an average price of $216.99, for a total transaction of $163,610.46. Following the transaction, the chief financial officer now owns 13,261 shares in the company, valued at approximately $2,877,504.39. The disclosure for this sale can be found here. 0.30% of the stock is currently owned by insiders.

Hedge Funds Weigh In On CME Group

A number of hedge funds have recently bought and sold shares of the company. Capital International Investors increased its stake in CME Group by 24.1% in the first quarter. Capital International Investors now owns 15,809,175 shares of the financial services provider’s stock valued at $3,403,557,000 after purchasing an additional 3,069,806 shares in the last quarter. PineStone Asset Management Inc. increased its stake in CME Group by 137.6% in the second quarter. PineStone Asset Management Inc. now owns 2,260,644 shares of the financial services provider’s stock valued at $444,443,000 after purchasing an additional 1,309,097 shares in the last quarter. M&G Plc bought a new stake in CME Group in the first quarter valued at $156,631,000. Assenagon Asset Management S.A. increased its stake in CME Group by 577.9% in the second quarter. Assenagon Asset Management S.A. now owns 645,330 shares of the financial services provider’s stock valued at $126,872,000 after purchasing an additional 550,133 shares in the last quarter. Finally, Ameriprise Financial Inc. increased its stake in CME Group by 11.3% in the second quarter. Ameriprise Financial Inc. now owns 5,283,196 shares of the financial services provider’s stock valued at $1,038,676,000 after purchasing an additional 537,758 shares in the last quarter. Institutional investors own 87.75% of the company’s stock.

About CME Group

CME Group Inc, together with its subsidiaries, operates contract markets for the trading of futures and options on futures contracts worldwide. It offers futures and options products based on interest rates, equity indexes, foreign exchange, agricultural commodities, energy, and metals, as well as fixed income and foreign currency trading services.